Fig. 1: Aurora B is overexpressed in OSCC tumor tissue.
From: Targeting Aurora B kinase with Tanshinone IIA suppresses tumor growth and overcomes radioresistance
A The representative immunoblotting (IB) results of Aurora B expression in 20 cases of matched OSCC patient tissues and adjacent non-tumor tissues (Mann–Whitney U test). T, tumor; N, adjacent non-tumor tissue. B IB analysis of Aurora B expression in hTERT-OME and OSCC cell lines. C Cell viability of SCC25 (left) and CAL27 (right) cells expressing shGFP or shAurora B. Top, IB analysis of Aurora B expression. Bottom, MTS analysis of cell viability. D Colony formation of CAL27 and SCC25 cells expressing shGFP or shAurora B; n = 3 independent biological replications, one-way ANOVA. Scale bar, 300 μm. E–G In vivo tumor growth of CAL27 cells expressing of shGFP or shAurora B. The tumor volume (E), the image of the tumor mass (F), and the weight of the tumor mass (G) of CAL27 xenograft tumors; n = 5 mice per group, one-way ANOVA. H–J In vivo tumor growth of SCC25 cells expressing of shGFP or shAurora B. The tumor volume (H), the image of the tumor mass (I), and the weight of the tumor mass (J) of SCC25 xenograft tumors; ***p < 0.001; n = 5 mice per group, one-way ANOVA. For F and I, scale bar, 1 cm.
